To build a convenient and sensitive predictive tool for clinical use, a new prognostic model based on the six-mRNA model was established by combining signature and four clinical risk factors (age, IDH1 status, MGMT status, and CIMP status) to predict 1-, 2-, and 3-years OS in GBM patients. This evidence concerns the gene IDH1 and glioblastoma.